How Accredo One Adherence™ is Transforming Injectable Therapy Support

Driving Better Outcomes Through Innovation

In the complex world of specialty medications, adherence is more than a metric—it’s a mission. Injectable therapies often vary in both dosage and timing— Injection schedules can be complicated by doses that change with weight or occur more or less often depending on factors like age or condition severity—some require weekly injections, while others are administered every four to six weeks —making it difficult for patients to establish a consistent routine.1 This complexity can disrupt adherence, especially when patients are managing other health conditions or traveling.

When patients stay on track with their injectable therapies, outcomes improve, and patients receive more consistent support throughout their treatment journey.2 That’s where the Accredo One Adherence™ program steps in, delivering a powerful blend of clinical expertise and digital innovation to elevate adherence and enhance the patient experience.

A Smarter Approach to Adherence

Developed in partnership with HealthBeacon, a leader in smart medication management tools, One Adherence integrates Accredo’s proven clinical care model with HealthBeacon’s Injection Care Management System (ICMS) and Companion App. This system supports patients using self-injectable therapies at home through a seamless, tech-enabled experience designed to reinforce adherence, improve engagement and provide a safe and convenient disposal method for used injectables:

• Smart Sharps Bin: A discreet unit that tracks injections in real time and securely holds a standard red sharps container—helping patients stay on schedule while maintaining a patient-friendly home setup.
• Companion App: Sends reminders, visualizes adherence scores, and offers live chat support to keep patients informed and connected.
• Mailback Kit: Enables convenient, safe, and sustainable sharps disposal from home.
• Customer Care: Bi-lingual, US-based care team available via phone, SMS, and live chat to provide timely support.

Together, these tools empower patients with timely prompts, personalized insights, and convenient access to support—right when and where they need it.

Technology That Drives Results

The One Adherence platform is more than a set of tools—it’s a connected ecosystem designed to turn passive behaviors into proactive care. When patients dispose of an injection in the Smart Sharps Bin, the device captures an image and a digital timestamp, creating a verified record of each dose and enabling real-time visibility into adherence patterns.

This data is securely transmitted to Accredo’s Therapeutic Resource Center® (TRC) clinicians, enabling timely outreach when doses are delayed.

The Companion App, developed and owned by HealthBeacon, deepens engagement by delivering personalized reminders, adherence score tracking, and offering easy chat access to the HealthBeacon Care Team for support. Among patients who enroll in Accredo One Adherence, 70% of patients onboard the Companion App, making it an invaluable patient engagement tool.

Even the Mailback Kit plays a role in adherence by simplifying sharps disposal, reinforcing routine use, and supporting sustainability. These integrated technologies not only enhance the patient experience, they generate actionable insights that help guide clinical support and improve therapy continuity.

Measurable Impact: Turning Insights into Outcomes

The One Adherence program combines real-time digital tracking with proactive clinical engagement to help improve adherence and support therapy continuity. By connecting patients with timely reminders and clinical outreach, the program contributes to more consistent medication use and stronger engagement.

An Accredo study of patients enrolled in One Adherence program compared to those not enrolled found that patients actively engaged with Accredo’s TRC clinicians achieved a 9.4% higher proportion of days covered (PDC) adherence rate. This improvement is especially meaningful in chronic and complex conditions, where even small gains in adherence may influence disease progression, quality of life, and overall therapy success.3

Program Highlights:3

• 15,000+ patients enrolled across multiple therapeutic areas
• 200,000+ injections tracked through smart technology
• 87% adherence rate within 72 hours of scheduled dosing, indicating timely administration of therapy
• 78% of clinical interventions led to improved adherence behavior

These results reflect the value of combining smart technology with timely, personalized clinical support. For care teams, this means greater visibility into patient adherence. For therapy stakeholders, it offers a scalable, data-informed model to help support long-term success.

A Commitment to Continuous Innovation

Accredo continues to evolve its digital ecosystem to better support patients and the teams who care for them. The One Adherence program builds on Accredo’s specialty pharmacy model—which includes patient equity solutions, specialty-trained staff, 24/7 support and access to interpretive services in more than 200 languages—by integrating smart technology and a unique care model that reinforces adherence.

As a part of Accredo’s Care Equity commitment, the One Adherence program is offered at no added cost to patients. In many cases, costs associated with Smart Sharps Bins are absorbed by the manufacturer, helping ensure patients can access enhanced support without financial barriers.

Explore how One Adherence can help support your patients and therapies at Accredo.com/pharma/oneadherence.

• 1

  Evernorth Health Services. Improving Drug Adherence for Inflammatory Conditions. Published April 2024. Accessed August 2025. https://www.evernorth.com/articles/improving-medication-adherence-inflammatory-conditions

• 2

  Accredo Specialty Pharmacy. Digital Tools: Adherence Study. Accredo. Published April 22, 2024. Accessed August 13, 2025. https://www.accredo.com/insights/use-digital-tools-and-positive-impact-patient-adherence

• 3

  Accredo Specialty Pharmacy. One Adherence Program Overview. Accessed August 2025. Accredo.com/pharma/oneadherence